Azitra Strengthens Global Intellectual Property Portfolio With Newly Granted And Allowed Patents

Author: Benzinga Newsdesk | July 23, 2024 08:12am

• Newly issued U.S. patent protects a filaggrin-secreting strain of Staphylococcus epidermidis for the treatment of atopic dermatitis. Issuance date was July 16, 2024
• Newly allowed patents in the U.S. and China protect the composition of a filaggrin-secreting strain of Staphylococcus epidermidis
• Newly allowed Canada patent protects a filaggrin-secreting strain of Staphylococcus epidermidis for a number of skin diseases, including atopic dermatitis
• Atopic dermatitis is a high unmet need with no FDA-approved treatment option and affects approximately 16.5 million people in the United States
  • Broadens Azitra's global intellectual property (IP) position for its platform using metagenomics and engineered skin bacteria for precision dermatology

Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. patent No. 12,036,248, covering future potential pipeline candidates for indications including atopic dermatitis, titled "Therapeutic treatment of skin disease with recombinant skin microorganisms."

Posted In: AZTR